MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway

Oncogene

Volumn 31, Issue 26, 2012, Pages 3136-3147

  Lorenzon, E ^a   Colladel, R ^a   Andreuzzi, E ^a,b   Marastoni, S ^a   Todaro, F ^a   Schiappacassi, M ^a   Ligresti, G ^c   Colombatti, A ^a,b   Mongiat, M ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

angiogenesis; extracellular matrix; VEGF

Indexed keywords

GLYCOPROTEIN; MULTIMERIN2; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, SURFACE; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84863219862     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.487     Document Type: Article

References (43)

1. Anghelina M, Krishnan P, Moldovan L, Moldovan NI. (2006). Monocytes/Macrophages cooperate with progenitor cells during neovascularization and tissue repair: conversion of cell columns into fibrovascular bundles. Am J Pathol 168: 529-541. (Pubitemid 43271151)
2. Aplin AC, Fogel E, Zorzi P, Nicosia RF. (2008). The aortic ring model of angiogenesis. Methods Enzymol 443: 119-136.
3. Boehm T, Folkman J, Browder T, O'Reilly MS. (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407. (Pubitemid 28027321)
4. Braghetta P, Ferrari A, De GP, Zanetti M, Volpin D, Bonaldo P et al. (2004). Overlapping, complementary and site-specific expression pattern of genes of the EMILIN/Multimerin family. Matrix Biol 22: 549-556. (Pubitemid 38283778)
5. Brekken RA, Huang X, King SW, Thorpe PE. (1998). Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 58: 1952-1959. (Pubitemid 28217472)
6. Campbell NE, Kellenberger L, Greenaway J, Moorehead RA, Linnerth-Petrik NM, Petrik J. (2010). Extracellular matrix proteins and tumor angiogenesis. J Oncol 2010: 586905.
7. Carmeliet P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395. (Pubitemid 30208155)
8. Chen TT, Luque A, Lee S, Anderson SM, Segura T, Iruela-Arispe ML. (2010). Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. J Cell Biol 188: 595-609.
9. Cheresh DA, Stupack DG. (2008). Regulation of angiogenesis: apoptotic cues from the ECM. Oncogene 27: 6285-6298.
10. Christian S, Ahorn H, Novatchkova M, Garin-Chesa P, Park JE, Weber G et al. (2001). Molecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endothelium. J Biol Chem 276: 48588-48595.
11. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991.
12. Ferrara N. (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29: 10-14.
13. Folkman J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
14. Gengrinovitch S, Berman B, David G, Witte L, Neufeld G, Ron D. (1999). Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem 274: 10816-10822.
15. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J. (2007). Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210: 807-818. (Pubitemid 46185050)
16. Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S et al. (2003). Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Letters 198: 107-117. (Pubitemid 37289110)
17. Holmqvist K, Cross MJ, Rolny C, Hagerkvist R, Rahimi N, Matsumoto T et al. (2004). The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 279: 22267-22275. (Pubitemid 38679423)
18. Hotz B, Backer MV, Backer JM, Buhr HJ, Hotz HG. (2010). Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer. Neoplasia 12: 797-806.
19. Hu M, Polyak K. (2008). Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18: 27-34. (Pubitemid 351694443)
20. Huber MA, Kraut N, Schweifer N, Dolznig H, Peter RU, Schubert RD et al. (2006). Expression of stromal cell markers in distinct compartments of human skin cancers. J Cutan Pathol 33: 145-155.
21. Hutchings H, Ortega N, Plouet J. (2003). Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J 17: 1520-1522.
22. Jaffe EA, Nachman RL, Becker CG, Minick CR. (1973). Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756.
23. Joyce JA, Pollard JW. (2009). Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
24. Koperek O, Scheuba C, Puri C, Birner P, Haslinger C, Rettig W et al. (2007). Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma. Int J Oncol 31: 59-67.
25. Kupprion C, Motamed K, Sage EH. (1998). SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 273: 29635-29640. (Pubitemid 28509972)
26. Lawler J. (2002). Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6: 1-12. (Pubitemid 44133979)
27. Ligresti G, Aplin AC, Zorzi P, Morishita A, Nicosia RF. (2011). Macrophage-derived tumor necrosis factor-a is an early component of the molecular cascade leading to angiogenesis in response to aortic injury. Arterioscler Thromb Vasc Biol 31: 1151-1159.
28. Mongiat M, Marastoni S, Ligresti G, Lorenzon E, Schiappacassi M, Perris R et al. (2010). The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment. Neoplasia 12: 294-304.
29. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV. (2003). Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278: 4238-4249. (Pubitemid 36801161)
30. Mustonen T, Alitalo K. (1995). Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129: 895-898.
31. Nicosia R. (2009). The aortic ring model of angiogenesis: a quarter century of search and discovery. J Cell Mol Med. 13: 4113-4136.
32. Nyberg P, Salo T, Kalluri R. (2008). Tumor microenvironment and angiogenesis. Front Biosci 13: 6537-6553.
33. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. (2006). VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
34. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H et al. (2006). Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66: 184-191. (Pubitemid 43166024)
35. Sahni A, Francis CW. (2000). Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 96: 3772-3778.
36. Sanz-Moncasi MP, Garin-Chesa P, Stockert E, Jaffe EA, Old LJ, Rettig WJ. (1994). Identification of a high molecular weight endothelial cell surface glycoprotein, endoGlyx-1, in normal and tumor blood vessels. Lab Invest 71: 366-373. (Pubitemid 24310016)
37. Spessotto P, Giacomello E, Perris R. (2000). Fluorescence assays to study cell adhesion and migration in vitro. Methods Mol Biol 139: 321-343.
38. Sun J, Hopkins BD, Tsujikawa K, Perruzzi C, Adini I, Swerlick R et al. (2009). Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol 296: H1344-H1351.
39. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D et al. (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579-1586.
40. Ventura E, Sassi F, Parodi A, Balza E, Borsi L, Castellani P et al. (2010). Alternative splicing of the angiogenesis associated extradomain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8. PLoS One 5: e9145.
41. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. (1994). Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995. (Pubitemid 24332901)
42. Wijelath ES, Murray J, Rahman S, Patel Y, Ishida A, Strand K et al. (2002). Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res 91: 25-31. (Pubitemid 34778938)
43. Zoeller JJ, Whitelock JM, Iozzo RV. (2009). Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol 28: 284-291.